| Targeting WEE1 kinase in cancer CJ Matheson, DS Backos, P Reigan Trends in pharmacological sciences 37 (10), 872-881, 2016 | 370 | 2016 |
| Strategies and approaches of targeting STAT3 for cancer treatment SL Furtek, DS Backos, CJ Matheson, P Reigan ACS chemical biology 11 (2), 308-318, 2016 | 369 | 2016 |
| Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ... Journal of medicinal chemistry 60 (5), 1746-1767, 2017 | 102 | 2017 |
| Selective targeting of RSK isoforms in cancer KA Casalvieri, CJ Matheson, DS Backos, P Reigan Trends in cancer 3 (4), 302-312, 2017 | 68 | 2017 |
| A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells CJ Matheson, S Venkataraman, V Amani, PS Harris, DS Backos, ... ACS chemical biology 11 (4), 921-930, 2016 | 66 | 2016 |
| Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration AB Krueger, DJ Drasin, WA Lea, AN Patrick, S Patnaik, DS Backos, ... Journal of Biological Chemistry 289 (23), 16349-16361, 2014 | 54 | 2014 |
| Trifluoroacetic Acid in 2,2,2‐Trifluoroethanol Facilitates SNAr Reactions of Heterocycles with Arylamines B Carbain, CR Coxon, H Lebraud, KJ Elliott, CJ Matheson, E Meschini, ... Chemistry–A European Journal 20 (8), 2311-2317, 2014 | 41 | 2014 |
| Maneb alters central carbon metabolism and thiol redox status in a toxicant model of Parkinson's disease CC Anderson, JO Marentette, AK Rauniyar, KM Prutton, M Khatri, ... Free Radical Biology and Medicine 162, 65-76, 2021 | 26 | 2021 |
| Molecular docking of substituted pteridinones and pyrimidines to the ATP-binding site of the N-terminal domain of RSK2 and associated MM/GBSA and molecular field datasets KA Casalvieri, CJ Matheson, DS Backos, P Reigan Data in brief 29, 105347, 2020 | 23 | 2020 |
| Structure-based screen identification of a mammalian Ste20-like kinase 4 (MST4) inhibitor with therapeutic potential for pituitary tumors W Xiong, CJ Matheson, M Xu, DS Backos, TS Mills, S Salian-Mehta, ... Molecular cancer therapeutics 15 (3), 412-420, 2016 | 21 | 2016 |
| Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles H Lebraud, CR Coxon, VS Archard, CM Bawn, B Carbain, CJ Matheson, ... Organic & biomolecular chemistry 12 (1), 141-148, 2014 | 21 | 2014 |
| Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors CJ Matheson, KA Casalvieri, DS Backos, M Minhajuddin, CT Jordan, ... European journal of medicinal chemistry 197, 112316, 2020 | 18 | 2020 |
| Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors SL Furtek, CJ Matheson, DS Backos, P Reigan Oncotarget 7 (47), 77998, 2016 | 18 | 2016 |
| RSK3: a regulator of pathological cardiac remodeling EC Martinez, CL Passariello, J Li, CJ Matheson, K Dodge‐Kafka, ... IUBMB life 67 (5), 331-337, 2015 | 17 | 2015 |
| 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase CJ Matheson, CR Coxon, R Bayliss, K Boxall, B Carbain, AM Fry, ... RSC Medicinal Chemistry 11 (6), 707-731, 2020 | 15 | 2020 |
| Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study KA Casalvieri, CJ Matheson, DS Backos, P Reigan Bioorganic & Medicinal Chemistry 28 (5), 115303, 2020 | 13 | 2020 |
| Development of Potent Pyrazolopyrimidinone‐Based WEE1 Inhibitors with Limited Single‐Agent Cytotoxicity for Cancer Therapy CJ Matheson, KA Casalvieri, DS Backos, P Reigan ChemMedChem 13 (16), 1681-1694, 2018 | 12 | 2018 |
| Structure-guided design of purine-based probes for selective Nek2 inhibition CR Coxon, C Wong, R Bayliss, K Boxall, KH Carr, AM Fry, IR Hardcastle, ... Oncotarget 8 (12), 19089, 2017 | 12 | 2017 |
| A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain B Tabakoff, W Ren, L Vanderlinden, LD Snell, CJ Matheson, ZJ Wang, ... European journal of pharmacology 784, 1-14, 2016 | 9 | 2016 |
| 118 2-arylamino-6-ethynylpurines as potent irreversible inhibitors of the mitotic kinase Nek2 B Carbain, R Bayliss, K Boxall, C Coxon, H Lebraud, C Matheson, ... European journal of cancer, 37, 2012 | 6 | 2012 |
